MR-L2

• Description :

  MR-L2 is a reversible and noncompetitive allosteric activator of long-isoform phosphodiesterase-4 (PDE4), activates representative PDE4 long-isoform variants (PDE4A4, PDE4B1, PDE4C3, PDE4D5) . MR-L2 suppresses PGE2-induced MDCK cell cyst formation with an EC50 of 1.2 μM[1].

• CAS Number :

  [2374703-19-0]

• UNSPSC :

  12352005

• Target :

  Phosphodiesterase (PDE)

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/mr-l2.html

• Purity :

  98.63

• Solubility :

  DMSO : 83.33 mg/mL (ultrasonic)

• Smiles :

  ClC1=C(F)C=C(C2=NN(CC(NCC3=CC(Cl)=CC(Cl)=C3)=O)C(CC)=N2)C=C1

• Molecular Formula :

  C19H16Cl3FN4O

• Molecular Weight :

  441.71

• References & Citations :

  [1]Omar F, et al. Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases. Proc Natl Acad Sci U S A. 2019 Jul 2;116 (27) :13320-13329.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  PDE4